- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04700566
Allograft Adipose Injectable for Vocal Fold Paralysis
Safety and Efficacy of Allograft Adipose Matrix Injectable for Glottal Insufficiency
Renuva is allograft adipose matrix commonly used as a filler in cosmetic procedures.
The investigators are studying this material as an injectable in the vocal fold to treat glottic insufficiency.
Currently, many products can be used as an injectable in the vocal fold to correct glottic insufficiency such as carbomethycellulose, hyaluronic acid, collagen derivatives and calcium hydroxyapatite amongst others. An ideal injectable would not impair the fibroelastic property of the vocal fold tissues and would integrate within the tissue of the vocal fold. Since Renuva has the property of stimulating adipogenesis by using growth factor and collagen, the investigators believe it could represent a good option in terms of safety and efficacy for vocal fold augmentation.
This study will assess the safety and efficacy of Renuva as a vocal fold injectable to treat glottic insufficiency.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background/Significance:
Vocal cord injection augmentation is commonly used to treat glottal insufficiency. Various materials are used for injection augmentation including autologous fat, hyaluronic acid, collagen, carboxymethylcellulose, and calcium hydroxyapatite. However, all of the current injection choices have individual limitations such as temporary effect, unpredictability due to variable resorption by the body, unfavorable mechanical properties, and challenging handling attributes. Hence, there is a need for a more ideal injection augmentation substance that is biocompatible, nonimmunogenic, able to traverse small gauge needles, easy to use, and facilitates long term or permanent effect when desired.
Intervention:
Unilateral injection augmentation with allograft adipose matrix injectable. Renuva ®, is commonly used as in injectable material in plastic surgery for treatment of small cosmetic irregularities. The injectable stimulates adipogenesis using key matrix proteins including collagen IV, collagen VI, FGF-2, and VEGF. The injectable does not contain any lipids, cellular fragments, or DNA content. In vitro and in vivo demonstrate that the injectable can stimulate adipose tissue generation. Given this important quality, allograft adipose matrix may provide vocal fold bulk for a longer period of time with favorable viscoelastic properties which would make it a desirable agent for vocal fold augmentation.
Objective:
Assess the safety profile and efficacy of allograft adipose matrix for use in injection augmentation Study Design: Single arm prospective clinical trial.
Methods:
50 patients with glottal insufficiency will be enrolled to receive vocal fold augmentation injection using an Allograft adipose matrix, commercially available as Renuva ® over a 24 months recruitment period.
Study endpoints:
Primary study endpoint will be the completion of 12 months of follow up post injection with safety monitoring. Secondary endpoints will include patient reported outcome measures (VHI, VFI, DI and EAT-10), blinded Cape-V voice assessment by experts and laryngeal videostroboscopy blinded assessment with the mVali tool.
Plan for analysis:
The study cohort will be analyzed via descriptive statistics of the primary outcome (safety) via incidence of both minor and major adverse events. Non-parametric statistics (Wilcoxon signed-rank test) will be used for comparisons of patient reported outcome measures and blinded evaluations of voice and videostroboscopy endpoints from post-intervention time points to pre-intervention baseline.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Recruiting
- University of Southern California
-
Contact:
- Karla O'Dell
- Phone Number: 323-442-5790
- Email: kodell@usc.edu
-
Contact:
- Michael Johns
- Phone Number: 3234425790
- Email: michael.johna@med.usc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Age ≥ 18 years old
- Unilateral vocal fold immobility with glottal insufficiency present for at least 2 weeks from onset
- Willingness to partake in study and follow-up as documented by signed informed consent
Exclusion Criteria:
- History of allergy/hypersensitivity to lidocaine or amide-based anesthetics
- Pregnancy
- Active infection or inflammation in the larynx (presence of acute laryngeal infection caused by bacteria/virus or fungus)
- Comorbid known laryngeal conditions including but not limited to vocal fold scar, vocal tremor, laryngeal dystonia, etc. that would warrant other interventions for optimal treatment
- History of laryngeal surgery
- Life expectancy of less than 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Injection of Renuva Allograft adipose matrix in vocal fold
Injection of Renuva Allograft Adipose matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
|
Injection of Renuva Allograft adipose Matrix in the vocal fold for vocal fold medialization and treatment of glottal insufficiency
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse recorded in participants after injection
Time Frame: 18 months
|
Monitoring of adverse events during the study period for each participant receiving a vocal fold injection with Renuva
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Voice outcomes as reported by patient questionnaire
Time Frame: 18 months
|
Voice Handicap Index (VHI-10) patient questionnaire at 0, 1, 3, 6, 12, and 18 months
|
18 months
|
Score on VALI - Voice Vibratory Assessment of laryngeal imaging
Time Frame: 18 months
|
Physician assessment of the stroboscopic examination (blinded) using the VALI scaleat day 0, and post injection 1, 3, 6, 12, and 18 months
|
18 months
|
Dyspnea Index as measured by patient questionnaire
Time Frame: 18 months
|
Dyspnea index questionnaired, filled at 0, 1months, 3 months, 6 months, 12 months, 18 months
|
18 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-19-00876
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vocal Fold Palsy
-
Massachusetts Eye and Ear InfirmaryCompletedVocal Fold ImmobilityUnited States
-
Massachusetts General HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedVocal Fold NodulesUnited States
-
Massachusetts Eye and Ear InfirmaryCompletedVocal Fold DevelopmentUnited States
-
University of California, Los AngelesNational Institute on Deafness and Other Communication Disorders (NIDCD)Not yet recruitingMid-membranous Vocal Fold Lesion
-
Tel-Aviv Sourasky Medical CenterRecruitingVocal Fold Polyp | Vocal Cord Cyst | Vocal Nodules in AdultsIsrael
-
Guangzhou First People's HospitalCompleted
-
University of PittsburghCompleted
-
Sofregen Medical, Inc.CompletedVocal Cord Paralysis | Vocal Cord Atrophy | Vocal Fold PalsyUnited States
-
Kringle Pharma, Inc.Recruiting
-
University College, LondonRecruitingNeurological Disorder | Ultrasound | Vocal Fold MovementUnited Kingdom
Clinical Trials on Renuva Allograft Adipose Matrix
-
Musculoskeletal Transplant FoundationCompleted
-
Musculoskeletal Transplant FoundationCompletedObesityUnited States
-
University of LouisvilleCompletedAlveolar Process DefectUnited States
-
University of Sao PauloCompleted
-
VIVEX Biologics, Inc.Active, not recruitingDegenerative Disc DiseaseUnited States
-
University of LouisvilleCompletedClinical EfficacyUnited States
-
Mansoura UniversityRecruitingIntrabony Periodontal DefectEgypt
-
The University of Texas Health Science Center at...TerminatedGingival RecessionUnited States
-
Zimmer BiometZimmer DentalCompletedGingival RecessionUnited States
-
University of LouisvilleCompleted